tiprankstipranks
Trending News
More News >
ZyVersa Therapeutics (ZVSA)
OTHER OTC:ZVSA
US Market
Advertisement

ZyVersa Therapeutics (ZVSA) Price & Analysis

Compare
201 Followers

ZVSA Stock Chart & Stats


ZyVersa Therapeutics News

ZVSA FAQ

What was ZyVersa Therapeutics’s price range in the past 12 months?
ZyVersa Therapeutics lowest stock price was $0.11 and its highest was $3.37 in the past 12 months.
    What is ZyVersa Therapeutics’s market cap?
    ZyVersa Therapeutics’s market cap is $1.20M.
      When is ZyVersa Therapeutics’s upcoming earnings report date?
      ZyVersa Therapeutics’s upcoming earnings report date is Nov 12, 2025 which is in 46 days.
        How were ZyVersa Therapeutics’s earnings last quarter?
        ZyVersa Therapeutics released its earnings results on Aug 13, 2025. The company reported -$0.46 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.46.
          Is ZyVersa Therapeutics overvalued?
          According to Wall Street analysts ZyVersa Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does ZyVersa Therapeutics pay dividends?
            ZyVersa Therapeutics does not currently pay dividends.
            What is ZyVersa Therapeutics’s EPS estimate?
            ZyVersa Therapeutics’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does ZyVersa Therapeutics have?
            ZyVersa Therapeutics has 8,095,921 shares outstanding.
              What happened to ZyVersa Therapeutics’s price movement after its last earnings report?
              ZyVersa Therapeutics reported an EPS of -$0.46 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.143%.
                Which hedge fund is a major shareholder of ZyVersa Therapeutics?
                Currently, no hedge funds are holding shares in ZVSA

                Company Description

                ZyVersa Therapeutics

                ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.

                ZyVersa Therapeutics (ZVSA) Earnings & Revenues

                Similar Stocks
                Company
                Price & Change
                Follow
                TNF Pharmaceuticals
                Scinai Immunotherapeutics
                Entero Therapeutics
                Protagenic Therapeutics
                PMGC Holdings

                Ownership Overview

                6.64%0.27%0.22%92.88%
                6.64%
                Insiders
                0.22% Other Institutional Investors
                92.88% Public Companies and
                Individual Investors

                Options Prices

                Currently, No data available
                ---
                Popular Stocks
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis